BACKGROUND: Tenofovir-containing antiviral therapy might result in acute renal failure and is able to induce tubular dysfunction with hypocalcemia. On the other hand, hypercalcemia induced by intoxication with colecalciferol has been described to induce renal failure in HIV-positive individuals as well. Here, the authors describe the unusual case of reversible renal failure due to hypercalcemia in a patient with low-dose colecalciferol substitution treated with tenofovir. CASE REPORT: A 31-year-old HIV-positive female, CDC stage C3, was admitted to the authors' hospital with progressive renal failure and hypercalcemia. Antiretroviral therapy consisted of tenofovir and emtricitabine in combination with efavirenz. Additionally, she was on low-dose vitamin D(3) substitution (25 microg/d) and calcium supplementation (500 mg/d) due to systemic steroid treatment. CONCLUSION: Additionally to regular control of renal function, serologic level of calcium should be supervised in patients concomitantly treated with tenofovir and colecalciferol.
BACKGROUND:Tenofovir-containing antiviral therapy might result in acute renal failure and is able to induce tubular dysfunction with hypocalcemia. On the other hand, hypercalcemia induced by intoxication with colecalciferol has been described to induce renal failure in HIV-positive individuals as well. Here, the authors describe the unusual case of reversible renal failure due to hypercalcemia in a patient with low-dose colecalciferol substitution treated with tenofovir. CASE REPORT: A 31-year-old HIV-positive female, CDC stage C3, was admitted to the authors' hospital with progressive renal failure and hypercalcemia. Antiretroviral therapy consisted of tenofovir and emtricitabine in combination with efavirenz. Additionally, she was on low-dose vitamin D(3) substitution (25 microg/d) and calcium supplementation (500 mg/d) due to systemic steroid treatment. CONCLUSION: Additionally to regular control of renal function, serologic level of calcium should be supervised in patients concomitantly treated with tenofovir and colecalciferol.
Authors: Wan Beom Park; Pyoeng Gyun Choe; Jae Hyun Jo; Sung-Han Kim; Ji Hwan Bang; Hong Bin Kim; Nam Joong Kim; Myoung-Don Oh; Kang Won Choe Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: N A Foudraine; E Hovenkamp; D W Notermans; P L Meenhorst; M R Klein; J M Lange; F Miedema; P Reiss Journal: AIDS Date: 1999-02-04 Impact factor: 4.177
Authors: Rachel I Gafni; Rohan Hazra; James C Reynolds; Frank Maldarelli; Antonella N Tullio; Ellen DeCarlo; Carol J Worrell; John F Flaherty; Kitty Yale; Brian P Kearney; Steven L Zeichner Journal: Pediatrics Date: 2006-08-21 Impact factor: 7.124